Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

This publication has 40 references indexed in Scilit:

• Lack of a Significant Drug Interaction between Raltegravir and Tenofovir
  Antimicrobial Agents and Chemotherapy, 2008
• Detection of Nonnucleoside Reverse‐Transcriptase Inhibitor–Resistant HIV‐1 after Discontinuation of Virologically Suppressive Antiretroviral Therapy
  Clinical Infectious Diseases, 2008
• Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection
  New England Journal of Medicine, 2008
• Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
  New England Journal of Medicine, 2008
• Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs
  Nature Medicine, 2008
• Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase
  AIDS, 2007
• Prevalence of Primary HIV‐1 Drug Resistance among Recently Infected Adolescents: A Multicenter Adolescent Medicine Trials Network for HIV/AIDS Interventions Study
  The Journal of Infectious Diseases, 2006
• Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance
  AIDS, 2006
• Switch from Efavirenz to Nevirapine Associated with Resolution of Efavirenz-Related Neuropsychiatric Adverse Events and Improvement in Lipid Profiles
  AIDS Patient Care and STDs, 2006
• The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease
  New England Journal of Medicine, 2001